Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases

被引：15

作者：

Bertani, Lorenzo ^{[1
]}

Antonioli, Luca ^{[2
]}

Fornai, Matteo ^{[2
]}

Tapete, Gherardo ^{[1
]}

Baiano Svizzero, Giovanni ^{[1
]}

Marchi, Santino ^{[1
]}

Blandizzi, Corrado ^{[2
]}

Costa, Francesco ^{[3
]}

机构：

[1] Pisa Univ Hosp, Dept Translat Res & New Technol Med & Surg, Unit Gastroenterol, Via Paradisa 2, I-56124 Pisa, Italy

[2] Univ Pisa, Dept Clin & Expt Med, Unit Pharmacol & Pharmacovigilance, Pisa, Italy

[3] Pisa Univ Hosp, Dept Gen Stugery & Gastroenterol, Unit Inflammatory Bowel Dis, Pisa, Italy

来源：

MINERVA GASTROENTEROLOGICA E DIETOLOGICA | 2019年 / 65卷 / 04期

关键词：

Inflammatory bowel diseases; Cytokines; Biological therapy; Tumor biomarkers; NECROSIS-FACTOR-ALPHA; SEVERE CROHNS-DISEASE; ANTI-TNF TREATMENTS; ULCERATIVE-COLITIS; INDUCTION THERAPY; GENE-EXPRESSION; T-CELL; MAINTENANCE THERAPY; MONOCLONAL-ANTIBODY; FECAL CALPROTECTIN;

D O I：

10.23736/S1121-421X.19.02621-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Cytokines play a central role in the pathogenesis of inflammatory bowel diseases. For this reason, the vast majority of biological therapies are aimed to block pro-inflammatory cytokines or their receptors. Although these drugs have modified the course of the disease due to their efficacy, a high rate of non-response or loss of response over time is still an important issue for clinicians. In this perspective, many studies have been conducted in recent years to individuate a reliable biomarker of therapeutic response. In this review, we discuss the role of cytokines involved in the pathogenesis and in the therapy of inflammatory bowel diseases, and their putative use as pharmacological biomarkers of therapy responsiveness.

引用

收藏

页码：298 / 308

页数：11

相关论文

共 97 条

[1] Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies [J].

Ahluwalia, Bani ;

Moraes, Luiza ;

Magnusson, Maria K. ;

Ohman, Lena .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (04) :379-389

[2] One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study [J].

Amiot, A. ;

Serrero, M. ;

Peyrin-Biroulet, L. ;

Filippi, J. ;

Pariente, B. ;

Roblin, X. ;

Buisson, A. ;

Stefanescu, C. ;

Trang-Poisson, C. ;

Altwegg, R. ;

Marteau, P. ;

Vaysse, T. ;

Bourrier, A. ;

Nancey, S. ;

Laharie, D. ;

Allez, M. ;

Savoye, G. ;

Moreau, J. ;

Vuitton, L. ;

Viennot, S. ;

Aubourg, A. ;

Pelletier, A. -L. ;

Bouguen, G. ;

Abitbol, V. ;

Gagniere, C. ;

Bouhnik, Y. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (03) :310-321

[3] In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease [J].

Atreya, Raja ;

Neumann, Helmut ;

Neufert, Clemens ;

Waldner, Maximilian J. ;

Billmeier, Ulrike ;

Zopf, Yurdaguel ;

Willma, Marcus ;

App, Christine ;

Muenster, Tino ;

Kessler, Hermann ;

Maas, Stefanie ;

Gebhardt, Bernd ;

Heimke-Brinck, Ralph ;

Reuter, Eva ;

Doerje, Frank ;

Rau, Tilman T. ;

Uter, Wolfgang ;

Wang, Thomas D. ;

Kiesslich, Ralf ;

Vieth, Michael ;

Hannappel, Ewald ;

Neurath, Markus F. .

NATURE MEDICINE, 2014, 20 (03) :313-318

[4] Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease [J].

Babyatsky, MW ;

Rossiter, G ;

Podolsky, DK .

GASTROENTEROLOGY, 1996, 110 (04) :975-984

[5] Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis [J].

Battat, Robert ;

Dulai, Parambir S. ;

Vande Casteele, Niels ;

Evans, Elisabeth ;

Hester, Kelly D. ;

Webster, Edvelyn ;

Jain, Anjali ;

Proudfoot, James A. ;

Mairalles, Ara ;

Neill, Jennifer ;

Singh, Siddharth ;

Chang, John T. ;

Rivera-Nieves, Jesus ;

Sandborn, William J. ;

Boland, Brigid S. .

INFLAMMATORY BOWEL DISEASES, 2019, 25 (02) :410-420

[6] Review article: loss of response to anti-TNF treatments in Crohn's disease [J].

Ben-Horin, S. ;

Chowers, Y. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (09) :987-995

[7] Optimizing anti-TNF treatments in inflammatory bowel disease [J].

Ben-Horin, Shomron ;

Kopylov, Uri ;

Chowers, Yehuda .

AUTOIMMUNITY REVIEWS, 2014, 13 (01) :24-30

[8]

Bertani L, 2019, GASTROENTEROLOGY, V156, pS654

[9] Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].

Bettelli, E ;

Carrier, YJ ;

Gao, WD ;

Korn, T ;

Strom, TB ;

Oukka, M ;

Weiner, HL ;

Kuchroo, VK .

NATURE, 2006, 441 (7090) :235-238

[10] Advances in understanding the role of cytokines in inflammatory bowel disease [J].

Bevivino, Gerolamo ;

Monteleone, Giovanni .

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 12 (09) :907-915

← 1 2 3 4 5 6 7 8 9 10 →